✦ LIBER ✦

A phase II study of spirogermanium in patients with metastatic malignant melanoma

✍ Scribed by Elizabeth Eisenhauer; Ian Kerr; Audley Bodurtha; Neill Iscoe; Peter McCulloch; Kathleen Pritchard; Ian Quirt

Publisher: Springer US
Year: 1985
Tongue: English
Weight: 205 KB
Volume: 3
Category: Article
ISSN: 0167-6997
DOI: 10.1007/bf00179436

No coin nor oath required. For personal study only.

✦ Synopsis

The National Cancer Institute of Canada Clinical Trials Group conducted a phase II study of spirogermanium given daily for 5 days every 3 weeks to previously untreated patients with malignant melanoma. In 21 evaluable patients one complete response was seen (response rate 5%). Disease progression occurred in the other 20 patients. Toxicity was primarily neurologic and mild or moderate in most patients, though there was one treatment related death. In this schedule spirogermanium has extremely limited activity against malignant melanoma and will not contribute significantly to the systemic therapy of this disease.

📜 SIMILAR VOLUMES

Phase II trial of fotemustine in patient

Phase II trial of fotemustine in patients with metastatic malignant melanoma

✍ Carla I. Falkson; Geoffrey Falkson; Hendré C. Falkson 📂 Article 📅 1994 🏛 Springer US 🌐 English ⚖ 318 KB

A phase II study of chlorozotocin in met

A phase II study of chlorozotocin in metastatic malignant melanoma

✍ Daniel F. Hoth; Philip S. Schein; Stanley Winokur; Paul V. Woolley; Kay Robichau 📂 Article 📅 1980 🏛 John Wiley and Sons 🌐 English ⚖ 713 KB

Treatment of metastatic malignant melano

Treatment of metastatic malignant melanoma with trimetrexate: A phase II study

✍ Odujinrin, Oluwole ;Goldberg, David ;Doroshow, James ;Leong, Lucille ;Margolin, 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 361 KB

## Abstract Trimetrexate glucuronate, a nonclassical antifolate, was administered to 14 patients with recurrent and progressive metastatic malignant melanoma. Thirteen patients were evaluable for response and toxicity. Five patients had received prior treatment consisting of immunotherapy (one pati

A phase II study of CCNU with benznidazo

A phase II study of CCNU with benznidazole for metastatic malignant melanoma

✍ Norman M. Bleehen; J. Trevor Roberts; Hugh F.V. Newman 📂 Article 📅 1986 🏛 Elsevier Science 🌐 English ⚖ 269 KB

A phase II study of autologous irradiate

A phase II study of autologous irradiated tumor cells plus BCG in patients with metastatic malignant melanoma

✍ J. Frederick Laucius; Audley J. Bodurtha; Michael J. Mastrangelo; Robert E. Bell 📂 Article 📅 1977 🏛 John Wiley and Sons 🌐 English ⚖ 285 KB 👁 2 views

Eighteen patients with surgically incurable metastatic malignant melanoma were treated with a mixture of irradiated (15,000 rads) autologous tumors cells (1-2 X 10(8)) and BCG (Glaxo, 2-4.5 X 10(6) organisms), which was injected intradermally (in five divided doses) every 2 weeks (X5). Four of 18 (2

Phase II study of subcutaneously adminis

Phase II study of subcutaneously administered 5-azacytidine (NSC-102816) in patients with metastatic malignant melanoma

✍ Bellet, Robert E. ;Catalano, R. B. ;Mastrangelo, Michael J. ;Berd, David 📂 Article 📅 1978 🏛 John Wiley and Sons 🌐 English ⚖ 268 KB

## Abstract Thirty (30) patients with advanced metastatic malignant melanoma refractory to DTIC (NSC‐45388) and a nitrosourea were treated with 5‐azacytidine (NSC‐102816). 5‐Azacytidine was administered subcutaneously at a dosage of 100 mg/m^2^/day for 10 days. Twenty‐six (26) patients were evaluab